## Th2 Cytokine Axis in Atopic Dermatitis **Key Point:** Interleukin-4 (IL-4) is the master cytokine driving Th2 differentiation and is central to the acute inflammatory phase of atopic dermatitis. ### IL-4 and Th2 Differentiation IL-4 acts on naive CD4^+^ T cells to: 1. Activate STAT6 signaling pathway 2. Induce expression of GATA-3 transcription factor 3. Promote differentiation into Th2 cells 4. Suppress Th1 differentiation (via IFN-γ antagonism) **Mnemonic:** **STAT6** = **S**ignal **T**ransducer and **A**ctivator of **T**ranscription **6** — the key IL-4 signaling molecule. ### IL-4 and IL-13 Partnership | Feature | IL-4 | IL-13 | |---------|------|-------| | **Primary role** | Th2 differentiation | IgE switching, barrier dysfunction | | **Source** | Th2 cells, mast cells, basophils | Th2 cells, mast cells | | **IgE induction** | Yes (via CD40-CD40L) | Yes (direct B cell effect) | | **Filaggrin suppression** | Indirect | Direct downregulation | | **Acute phase dominance** | **Most important** | Chronic phase | **High-Yield:** IL-4 is the initiating cytokine in acute atopic dermatitis; IL-13 becomes more prominent in chronic lesions and further impairs barrier function. ### Clinical Relevance - **Dupilumab** (anti-IL-4 receptor α) blocks both IL-4 and IL-13 signaling — one of the most effective biologic therapies for moderate-to-severe AD - Elevated serum IL-4 levels correlate with disease activity - IL-4 promotes IgE class switching, leading to allergen-specific IgE production **Clinical Pearl:** The Th2 response in atopic dermatitis is characterized by IL-4, IL-5 (eosinophil recruitment), and IL-13, creating a self-perpetuating inflammatory loop. [cite:Harrison 21e Ch 297] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.